Published in Postgrad Med J on July 01, 1978
Prediction of outcome in dilated cardiomyopathy. Br Heart J (1987) 1.35
Correlations of fibrosis in endomyocardial biopsies from patients with aortic valve disease. Br Heart J (1980) 1.00
Prevalence of overt dilated cardiomyopathy in two regions of England. Br Heart J (1985) 0.90
The course of idiopathic dilated cardiomyopathy in New Zealand. Br Heart J (1987) 0.89
Assessment of heart neurons in dilated (congestive) cardiomyopathy. Br Heart J (1982) 0.83
Left bundle branch block, an old-new entity. J Cardiovasc Transl Res (2012) 0.82
What explains black-white differences in survival in idiopathic dilated cardiomyopathy? The Washington, DC, Dilated Cardiomyopathy Study. J Natl Med Assoc (1997) 0.81
Special investigations of COCM: endomyocardial biopsies (morphological analysis). Postgrad Med J (1978) 0.79
Endomyocardial biopsy: its history, techniques and current indications. Can Med Assoc J (1982) 0.78
Electron microscopy: an essential tool for morphological diagnosis? Br Med J (Clin Res Ed) (1982) 0.75
Maximum utilization of the life table method in analyzing survival. J Chronic Dis (1958) 22.07
Catheter technique for recording His bundle activity in man. Circulation (1969) 6.01
The cardiomyopathies. Br Heart J (1972) 3.14
The electrocardiogram of myocardopathy. Prog Cardiovasc Dis (1970) 1.02
[Diagnostic and prognostic value of endomyocardial biopsy in patients with congestive cardiomyopathy (author's transl)]rdiomyopathy(author. Dtsch Med Wochenschr (1975) 1.00
Lithium substitution and the distribution of sodium in the rat tail artery. Circ Res (1974) 0.98
DNA content and DNA synthesis in the myocardium of rats after induced renal hypertension. Cardiovasc Res (1974) 0.97
[Myocardial biopsy in congestive myocardiopathies of apparently primary origin]. Arch Mal Coeur Vaiss (1976) 0.88
[Effect of alcohol on the heart including alcoholic cardiomyopathy]. Internist (Berl) (1978) 0.87
[Significance of electrocardiography in the diagnosis and course observation of patients with congestive cardiomyopathy]. Z Kardiol (1974) 0.86
[Complete left branch block with strong left axial deviation of the qrs. ii. Anatomical study]. Arch Mal Coeur Vaiss (1974) 0.82
Failure of demand pacing with small surface area electrodes. Circulation (1976) 0.82
[Hemodynamics of the pulmonary circulation during a multistep exercise test in healthy subjects]. Med Welt (1976) 0.82
[Congestive cardiomyopathy]. Med Welt (1973) 0.82
Genotype-phenotype correlation in the long-QT syndrome: gene-specific triggers for life-threatening arrhythmias. Circulation (2001) 7.47
Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature (1998) 7.26
Task Force on Sudden Cardiac Death of the European Society of Cardiology. Eur Heart J (2001) 2.93
Inhibitors of angiotensin-converting enzyme prevent myointimal proliferation after vascular injury. Science (1989) 2.46
Detection of surface antigen 17-1A in breast and colorectal cancer. Hybridoma (1999) 2.45
Post-infarction depression and incomplete recovery 6 months after acute myocardial infarction. Lancet (1994) 2.39
Specific inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase. Proc Natl Acad Sci U S A (1992) 2.22
xIAP induces cell-cycle arrest and activates nuclear factor-kappaB : new survival pathways disabled by caspase-mediated cleavage during apoptosis of human endothelial cells. Circ Res (2001) 2.10
Left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy: increase in gradient after exercise. J Am Coll Cardiol (1992) 2.06
Clinical evaluation of no-carrier-added meta-[123I]iodobenzylguanidine for myocardial scintigraphy. Eur J Nucl Med (2000) 2.06
Percutaneous coronary excimer laser angioplasty in patients with stable and unstable angina pectoris. Acute results and incidence of restenosis during 6-month follow-up. Circulation (1990) 2.05
A prognostic computer model to individually predict post-procedural complications in interventional cardiology: the INTERVENT Project. Eur Heart J (1999) 1.98
The potential for QT prolongation and proarrhythmia by non-antiarrhythmic drugs: clinical and regulatory implications. Report on a policy conference of the European Society of Cardiology. Eur Heart J (2000) 1.92
KCNE1 mutations cause jervell and Lange-Nielsen syndrome. Nat Genet (1997) 1.90
De novo mutation in the SCN5A gene associated with early onset of sudden infant death. Circulation (2001) 1.88
Lipoprotein(a) is an independent risk factor for myocardial infarction at a young age. Clin Chem (1990) 1.75
The natural history of aortic valve stenosis. Eur Heart J (1988) 1.72
Targeting the slow pathway for atrioventricular nodal reentrant tachycardia: initial results and long-term follow-up in 379 consecutive patients. Eur Heart J (2001) 1.71
The potential for QT prolongation and pro-arrhythmia by non-anti-arrhythmic drugs: clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res (2000) 1.70
Molecular diagnosis in a child with sudden infant death syndrome. Lancet (2001) 1.66
Standards for analysis of ventricular late potentials using high-resolution or signal-averaged electrocardiography: a statement by a task force committee of the European Society of Cardiology, the American Heart Association, and the American College of Cardiology. J Am Coll Cardiol (1991) 1.63
A site-directed mutagenesis study to identify amino acid residues involved in the catalytic function of the restriction endonuclease EcoRV. Biochemistry (1992) 1.62
A prognostic computer model to predict individual outcome in interventional cardiology. The INTERVENT Project. Eur Heart J (1997) 1.61
Efficacy of antiarrhythmic drugs in patients with arrhythmogenic right ventricular disease. Results in patients with inducible and noninducible ventricular tachycardia. Circulation (1992) 1.61
An anatomically and electrogram-guided stepwise approach for effective and safe catheter ablation of the fast pathway for elimination of atrioventricular node reentrant tachycardia. J Am Coll Cardiol (1995) 1.61
[Inadequate therapies with implantable cardioverter-defibrillators--incidence, etiology, predictive factors and preventive strategies]. Z Kardiol (1996) 1.59
A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the Dialysis-versus-Diuresis (DVD) Trial. Clin Res Cardiol (2006) 1.59
Effects of angiotensin converting enzyme inhibitors and of hydralazine on endothelial function in hypertensive rats. Hypertension (1990) 1.58
A novel long-QT 5 gene mutation in the C-terminus (V109I) is associated with a mild phenotype. J Mol Med (Berl) (2001) 1.56
Endocardial radiofrequency ablation of septal hypertrophy. A new catheter-based modality of gradient reduction in hypertrophic obstructive cardiomyopathy. Z Kardiol (2004) 1.55
Erroneous discharge of an implantable cardioverter defibrillator caused by an electric razor. Pacing Clin Electrophysiol (1995) 1.54
Catheter-based therapy for hypertrophic obstructive cardiomyopathy. First in-hospital outcome analysis of the German TASH Registry. Z Kardiol (2004) 1.53
Prevalence of coronary artery disease in a general population without suspicion of coronary artery disease: angiographic analysis of subjects aged 40 to 70 years referred for catheter ablation therapy. Eur Heart J (2000) 1.52
Intraoperative radiofrequency ablation of chronic atrial fibrillation: a left atrial curative approach by elimination of anatomic "anchor" reentrant circuits. J Cardiovasc Electrophysiol (1999) 1.52
Is there a need for routine testing of ICD defibrillation capacity? Results from more than 1000 studies. Eur Heart J (2000) 1.51
Factors influencing breath condensate volume. Pneumologie (2001) 1.51
Extracardiac contributions to chest pain perception in patients 6 months after acute myocardial infarction. Am Heart J (1999) 1.50
Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. J Am Coll Cardiol (1999) 1.49
Successful radiofrequency catheter ablation of right sided accessory pathways during sustained atrial fibrillation. Eur Heart J (1995) 1.47
Increased risk of bacterial endocarditis in inflammatory bowel disease. Am J Med (1992) 1.47
Task Force Report: The legal implications of medical guidelines--a Task Force of the European Society of Cardiology. Eur Heart J (1999) 1.47
Association of the GPIa C807T and GPIIIa PlA1/A2 polymorphisms with premature myocardial infarction in men. Eur Heart J (2002) 1.47
Diastolic filling pattern and left ventricular diameter predict response and prognosis after cardiac resynchronisation therapy. Heart (2007) 1.45
Atrial fibrillation: current knowledge and recommendations for management. Working Group on Arrhythmias of the European Society of Cardiology. Eur Heart J (1998) 1.44
Doppler echocardiographic assessment of the pressure gradient during bicycle ergometry in hypertrophic cardiomyopathy. Am J Cardiol (1992) 1.43
[Rupture of the pulmonary artery - fatal complication by pulmonary artery balloon-tipped catheter]. Z Kardiol (1999) 1.42
Ro 44-9883, a new nonpeptide glycoprotein IIb/IIIa antagonist, prevents platelet loss during experimental cardiopulmonary bypass. J Thorac Cardiovasc Surg (1993) 1.42
[18-year old patient with anti-epileptic therapy and sudden cardiac death]. Z Kardiol (2003) 1.41
[Heart muscle biopsy in dilated cardiomyopathy]. Internist (Berl) (2006) 1.41
'The abrupt no-flow': a no-reflow like phenomenon in hypertrophic cardiomyopathy. Eur Heart J (2002) 1.41
Hemodynamic findings in patients with left bundle branch block after myectomy in hypertrophic obstructive cardiomyopathy (HOCM) Eur J Cardiothorac Surg (1993) 1.40
The Percutaneous Cardiac Mapping and Ablation Registry: final summary of results. Pacing Clin Electrophysiol (1988) 1.39
Patients with valvular heart disease presenting with sustained ventricular tachyarrhythmias or syncope: results of programmed ventricular stimulation and long-term follow-up. Circulation (1997) 1.39
Temperature-controlled radiofrequency catheter ablation of manifest accessory pathways. Eur Heart J (1996) 1.39
Affective disorders and survival after acute myocardial infarction. Results from the post-infarction late potential study. Eur Heart J (1991) 1.39
Percutaneous coronary interventions using a new 5 French guiding catheter: results of a prospective study. Catheter Cardiovasc Interv (2001) 1.39
Evaluation of antiarrhythmic drug efficacy in patients with an ICD: unlimited potential or replete with complexity and problems? J Cardiovasc Electrophysiol (1999) 1.39
Effects of enflurane on inducibility of ventricular tachycardia. Am J Cardiol (1991) 1.38
Implantable cardioverter/defibrillators (ICD): a new lead-system using transvenous-subcutaneous approach in patients with prior cardiac surgery. Eur J Cardiothorac Surg (1991) 1.38
Contribution of heart rate variability to long-term risk stratification after myocardial infarction. Eur Heart J (1997) 1.38
Dynamics of mitral regurgitant flow and orifice area. Physiologic application of the proximal flow convergence method: clinical data and experimental testing. Circulation (1994) 1.38
Extracellular matrix deposition by primary human lung fibroblasts in response to TGF-beta1 and TGF-beta3. Am J Physiol (1999) 1.36
Systemic inflammatory parameters in patients with atherosclerosis of the coronary and peripheral arteries. Arterioscler Thromb Vasc Biol (1999) 1.34
Site-directed mutagenesis studies with EcoRV restriction endonuclease to identify regions involved in recognition and catalysis. Biochemistry (1991) 1.32
Mg2+ confers DNA binding specificity to the EcoRV restriction endonuclease. Biochemistry (1992) 1.27
Isolated noncompaction of the left ventricular myocardium -- a review of the literature two decades after the initial case description. Clin Res Cardiol (2007) 1.18
[Basal cell adenocarcinoma of the parotid gland: a rare tumor entity. Case report and review of the literature]. HNO (1998) 1.18
The LQT syndromes--current status of molecular mechanisms. Z Kardiol (1999) 1.18
Regional myocardial sympathetic dysinnervation in arrhythmogenic right ventricular cardiomyopathy. An analysis using 123I-meta-iodobenzylguanidine scintigraphy. Circulation (1994) 1.17
Potential benefit from implantable cardioverter-defibrillator therapy in patients with and without heart failure. Circulation (1998) 1.16
Prognostic significance of late ventricular potentials after acute myocardial infarction. Eur Heart J (1983) 1.15
Long QT syndrome and life threatening arrhythmia in a newborn: molecular diagnosis and treatment response. Heart (2004) 1.13
Single-incision implantation of cardioverter defibrillators using nonthoracotomy lead systems. Ann Thorac Surg (1994) 1.12
Experimental models of torsade de pointes. Cardiovasc Res (1998) 1.11
Peptide nucleic acid-assisted topological labeling of duplex dna. Methods (2001) 1.11
Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT). Eur Heart J (1999) 1.10
Potential benefit from implantable cardioverter-defibrillator therapy in children and young adolescents. Heart (2004) 1.09
Recording of left atrial potentials from pulmonary artery in man. Br Heart J (1980) 1.09
Biphasic defibrillation using a single capacitor with large capacitance: reduction of peak voltages and ICD device size. Pacing Clin Electrophysiol (1996) 1.08
Collagen type III induced ex vivo thrombogenesis in humans. Role of platelets and leukocytes in deposition of fibrin. Arteriosclerosis (1990) 1.06
Pacemaker-induced ventricular tachycardia in normally functioning ventricular demand pacemakers. Am J Cardiol (1989) 1.06
Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early afterdepolarizations in an intact heart model of LQT3. Basic Res Cardiol (2005) 1.05
Relation of serum levels of sex hormone binding globulin to coronary heart disease in postmenopausal women. Am J Cardiol (2002) 1.05
Task Force on Sudden Cardiac Death, European Society of Cardiology. Europace (2002) 1.05
Fetoscopic transesophageal electrocardiography and stimulation in fetal sheep: a minimally invasive approach aimed at diagnosis and termination of therapy-refractory supraventricular tachycardias in human fetuses. Circulation (1999) 1.04
Endothelial dysfunction and subendothelial monocyte macrophages in hypertension. Effect of angiotensin converting enzyme inhibition. Hypertension (1991) 1.04
Effects of verapamil on sinus node function in man. Eur J Cardiol (1978) 1.04
Radiofrequency coagulation of ventricular myocardium: improved prediction of lesion size by monitoring catheter tip temperature. Eur Heart J (1989) 1.04
DNA binding specificity of the EcoRV restriction endonuclease is increased by Mg2+ binding to a metal ion binding site distinct from the catalytic center of the enzyme. Biochemistry (1995) 1.03
Brugada syndrome and supraventricular tachyarrhythmias: a novel association? J Cardiovasc Electrophysiol (2001) 1.02
QRS duration: a simple marker for predicting cardiac mortality in ICD patients with heart failure. Heart (2003) 1.02
Effect of a new somatostatin analogue on pancreatic function in healthy volunteers. Pancreas (1986) 1.01